Stealth BioTherapeutics Showcases New Nonclinical Data From Duchenne Muscular Dystrophy Program
Stealth BioTherapeutics Corp (NASDAQ: MITO) presented
Stealth Biotherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data At The 2022 Muscular Dystrophy Association And Clinical And Scientific Conference
Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today
Stealth BioTherapeutics Granted U.S. Patent Titled ‘Compositions & methods for the treatment of amyotrophic lateral sclerosis, Parkinson’s disease, Parkinson’s disease w/dementia, dementia w/Lewy bodies & multiple system atrophy’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11273149.PN.&OS=PN/11273149&RS=PN/11273149
63 Biggest Movers From Yesterday
Gainers
Tenneco Inc. (NYSE: TEN) shares surged 93.9% to close at $19.35 on Wednesday after the company announced it will be acquired by Apollo Funds. Tenneco also reported a Q4 loss of $0.11 per share.
MITO: Seeking to Repair Mitochondria to Solve Unsolvable Medical Conditions
By Brad Sorensen, CFA
NASDAQ:MITO
READ THE FULL MITO RESEARCH REPORT
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
